Inventor · disambiguated record
Muthiah Manoharan
Also filed as: MANOHARAN MUTHIAH
323 granted patents·173 pending applications·23,893 citations·filing 1992–2025
99Inventor score
Files withALNYLAM PHARMACEUTICALS INC195ISIS PHARMACEUTICALS INC124MANOHARAN MUTHIAH49ARBUTUS BIOPHARMA CORP27ALNYLAM PHARMACEUTICALS7
Top patents by PatentIndex Score
496 records- 0199US10806791B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Oct 20, 2020·14 cites·12 claims
- 0299US9796974B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Oct 24, 2017·119 cites·30 claims
- 0399US9682139B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2015·Granted Jun 20, 2017·46 cites·20 claims
- 0499US9352048B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted May 31, 2016·112 cites·20 claims
- 0599US8344125B2Modified iRNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2009·Granted Jan 1, 2013·103 cites·20 claims
- 0699US8106022B2Carbohydrate conjugates as delivery agents for oligonucleotidesMANOHARAN MUTHIAH·Filed 2008·Granted Jan 31, 2012·588 cites·21 claims
- 0799USRE39464EOligonucleolotides having site specific chiral phosphorothioate internucleoside linkagesISIS PHARMACEUTICALS INC·Filed 2004·Granted Jan 9, 2007·235 cites·64 claims
- 0899US7041816B2Process for the synthesis of oligomeric compoundsISIS PHARMACEUTICALS INC·Filed 2004·Granted May 9, 2006·240 cites·17 claims
- 0999US6878805B2Peptide-conjugated oligomeric compoundsISIS PHARMACEUTICALS INC·Filed 2002·Granted Apr 12, 2005·218 cites·38 claims
- 1099US6858715B2Process for the synthesis of oligomeric compoundsISIS PHARMACEUTICALS INC·Filed 2002·Granted Feb 22, 2005·214 cites·35 claims
- 1199US6660720B2Targeted oligonucleotide conjugatesISIS PHARMACEUTICALS INC·Filed 2002·Granted Dec 9, 2003·168 cites·10 claims
- 1299US6600032B12′-O-aminoethyloxyethyl-modified oligonucleotidesISIS PHARMACEUTICALS INC·Filed 1999·Granted Jul 29, 2003·338 cites·31 claims
- 1399US6525031B2Targeted Oligonucleotide conjugatesISIS PHARMACEUTICALS INC·Filed 2001·Granted Feb 25, 2003·256 cites·22 claims
- 1499US5681941ASubstituted purines and oligonucleotide cross-linkingISIS PHARMACEUTICALS INC·Filed 1994·Granted Oct 28, 1997·1.4k cites·79 claims
- 1599US5587469AOligonucleotides containing N-2 substituted purinesISIS PHARMACEUTICALS INC·Filed 1995·Granted Dec 24, 1996·1.4k cites·29 claims
- 1699US5578718AThiol-derivatized nucleosidesISIS PHARMACEUTICALS INC·Filed 1993·Granted Nov 26, 1996·1k cites·25 claims
- 1798US11679158B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jun 20, 2023·7 cites·13 claims
- 1898US11633479B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 25, 2023·11 cites·24 claims
- 1998US11633480B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 25, 2023·11 cites·28 claims
- 2098US11612657B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Mar 28, 2023·9 cites·30 claims
- 2198US11590229B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Feb 28, 2023·11 cites·29 claims
- 2298US11406716B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Aug 9, 2022·8 cites·21 claims
- 2398US11382979B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jul 12, 2022·18 cites·30 claims
- 2498US11246933B1Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Feb 15, 2022·30 cites·28 claims
- 2598US11110174B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Sep 7, 2021·10 cites·20 claims
- 2698US10668170B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Jun 2, 2020·22 cites·22 claims
- 2798US10612024B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Apr 7, 2020·15 cites·35 claims
- 2898US10612027B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Apr 7, 2020·26 cites·25 claims
- 2998US10369226B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Aug 6, 2019·25 cites·42 claims
- 3098US10233448B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Mar 19, 2019·37 cites·40 claims
- 3198US9867882B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jan 16, 2018·33 cites·29 claims
- 3298US9399775B2RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Jul 26, 2016·51 cites·36 claims
- 3398US9345780B2Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic componentsTEKMIRA PHARMACEUTICALS CORP·Filed 2013·Granted May 24, 2016·255 cites·10 claims
- 3498US9249415B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Feb 2, 2016·24 cites·30 claims
- 3598US9186325B2Lipids and compositions for the delivery of therapeuticsMANOHARAN MUTHIAH·Filed 2009·Granted Nov 17, 2015·100 cites·19 claims
- 3698US9061063B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Jun 23, 2015·41 cites·32 claims
- 3798US9012498B2Biodegradable lipids for the delivery of active agentsMANOHARAN MUTHIAH·Filed 2011·Granted Apr 21, 2015·104 cites·41 claims
- 3898US8999351B2Lipids and compositions for the delivery of therapeuticsMANOHARAN MUTHIAH·Filed 2009·Granted Apr 7, 2015·102 cites·15 claims
- 3998US8883202B2Lipid compositionsMANOHARAN MUTHIAH·Filed 2010·Granted Nov 11, 2014·104 cites·22 claims
- 4098US8828956B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Sep 9, 2014·224 cites·16 claims
- 4198US8809516B2Therapeutic compositionsALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Aug 19, 2014·43 cites·22 claims
- 4298US8642076B2Lipid containing formulationsMANOHARAN MUTHIAH·Filed 2011·Granted Feb 4, 2014·155 cites·28 claims
- 4398US8575123B2Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic componentsMANOHARAN MUTHIAH·Filed 2009·Granted Nov 5, 2013·82 cites·39 claims
- 4498US8450467B2Carbohydrate conjugates as delivery agents for oligonucleotidesMANOHARAN MUTHIAH·Filed 2011·Granted May 28, 2013·227 cites·21 claims
- 4598US8404862B2Ligand-conjugated monomersMANOHARAN MUTHIAH·Filed 2009·Granted Mar 26, 2013·84 cites·40 claims
- 4698US7745608B2Modified iRNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2004·Granted Jun 29, 2010·129 cites·43 claims
- 4798US7723509B2IRNA agents with biocleavable tethersALNYLAM PHARMACEUTICALS·Filed 2004·Granted May 25, 2010·202 cites·41 claims
- 4898US7582744B2Chemically modified oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2005·Granted Sep 1, 2009·177 cites·23 claims
- 4998US7202264B2Supports for oligomer synthesisISIS PHARMACEUTICALS INC·Filed 2004·Granted Apr 10, 2007·90 cites·34 claims
- 5098US6861514B2Nucleosidic and non-nucleosidic folate conjugatesISIS PHARMACEUTICALS INC·Filed 2001·Granted Mar 1, 2005·122 cites·33 claims
Showing the top 50 of 496 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Muthiah Manoharan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →